Overview

Omthera Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular disease. Epanova, its product candidate, is a late-stage, omega-three free fatty acid composition that reduces triglycerides, improves other key lipid parameters. Epanova is a coated soft gelatin capsule containing a complex mixture of polyunsaturated free fatty acids derived from fish oils, including multiple long-chain omega-three and omega-six fatty acids, with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid being the most abundant forms of omega-three fatty acids. The Company has completed pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova.

Endorsements